Understanding Cellectis and Its Share Capital
Cellectis is a prominent player in the biotechnology sector, known for its innovative approaches to gene editing and immune therapies. As a company committed to advancing the field of genomics, Cellectis continuously updates its investors on essential company metrics.
Latest Share Capital Information
As of the latest reporting period, Cellectis has recorded significant figures in its share capital and voting rights, relevant for both current and prospective investors. The total number of shares has reached an impressive count, which further underlines the company's growth trajectory.
Key Metrics
On November 30, the company reported a total of 100,093,873 shares in its capital structure. Among these, the total number of voting rights stands at 88,576,206, indicating a healthy participation of shareholders in corporate governance.
Market Position
Cellectis is primarily listed on the Euronext Growth market, indicating its strategic positioning within the biotechnology arena. The company operates with the ISIN code: FR0010425595, which allows for easier tracking of its share performance.
Why These Figures Matter
Understanding the total number of shares and voting rights is crucial for investors. It provides insights into ownership dilution, voting power, and the overall market perception of the company. The statistics also play an essential role during annual meetings and shareholder votes, ensuring that shareholders have a voice in the company's direction.
Contacting Cellectis for More Information
Cellectis encourages inquiries from investors, media representatives, and partners. For media relations, Pascalyne Wilson, the Director of Communications, can be contacted at +33 (0)7 76 99 14 33 or via email at media@cellectis.com. Additionally, Patricia Sosa Navarro, Chief of Staff to the CEO, is available at +33 (0)7 76 77 46 93.
Investor Relations
For investor relations, reach out to Arthur Stril, the Interim Chief Financial Officer, at +1 (347) 809 5980 or email investors@cellectis.com. This dedicated team is ready to assist with queries regarding financial performance, shareholder services, and updates on company activity.
Frequently Asked Questions
What is the significance of Cellectis' share capital information?
Share capital information is vital as it indicates the number of shares and voting rights available to investors, impacting their decision-making and influence in the company.
Where is Cellectis listed?
Cellectis is listed on the Euronext Growth market, which provides a platform for various biotech companies.
How many total shares does Cellectis have?
As of the latest report, Cellectis has a total of 100,093,873 shares.
Who can I contact for media inquiries?
For media inquiries, you can reach Pascalyne Wilson at +33 (0)7 76 99 14 33 or via email at media@cellectis.com.
What are Cellectis' voting rights?
Cellectis holds a total of 88,576,206 voting rights, allowing shareholders to participate in corporate governance matters.